Optimización de la terapia con lopinavir/ritonavir en pacientes infectados por el VIH: aplicación de criterios farmacocinéticos y farmacogenéticos
[EN] Lopinavir/ritonavir (LPV/r) has demonstrated virological and immunological efficacy in the combined antiretroviral treatment (cART), in both naïve and experienced patients. Furthermore, LPV/r showed a high barrier to the development of resistance. Although generally well tolerated, adverse gastrointestinal side effects and metabolic disorders are frequent. Different tools that are used to optimize the cART with this drug in the daily clinical practice, emphasizing the therapeutic drug monitoring (TDM) of LPV/r and the genetic analysis of the main enzymes responsible for the metabolism and transport, are reviewed. The relationship between phenotype and genotype, established through TDM, could be useful for the physician to improve the clinical management of the HIV infection, due to the possibility of individualize the dose with this drug. It is also reviewed the monotherapy as a new strategy used in the simplification of the therapy with this drug, which could increase security and reduce costs.
Tesis y disertaciones académicas, Universidad de Salamanca (España), Academic dissertations, SIDA, Virus del SIDA, Farmacogenética, Medicamentos - Monitorización, AIDS (Disease), Drug monitoring, HIV (Viruses), Pharmacogenetics
Networked Digital Library of Theses and Dissertations